Cardiovascular biomarkers better after metabolic surgery for diabetes
Improvements in markers of dyslipidaemia, inflammation, thrombosis and glycaemia, say authors
Cardiovascular biomarkers in people with type 2 diabetes improve more after metabolic surgery than with medical therapy, a US study shows.
Harvard University researchers compared 12 cardiovascular biomarkers after up to five years in 100 patients with type 2 diabetes and a BMI between 27-43kg/m2.
The analysis used results from patients in the STAMPEDE study, who were randomised to either intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy.
Apolipoprotein A-I, high-sensitivity CRP and plasminogen activator inhibitor-1 improved significantly more in both surgical groups than in the medical group, the researchers reported in the Journal of the American College of Cardiology.
